July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Is Obstructive Sleep Apnoea Associated with Glaucoma Progression?
Author Affiliations & Notes
  • Rupert R A Bourne
    Vision & Eye Research Unit, Anglia Ruskin University, Hartford, ENGLAND, United Kingdom
    Dept of Ophthalmology, North West Anglia Foundation Trust, Huntingdon, Cambridgeshire, United Kingdom
  • Dariusz R Wozniak
    Respiratory Support and Sleep Centre, Papworth Hospital, Papworth, United Kingdom
  • Gil Peretz
    Assaf Harofeh medical center, Tel Aviv, Israel
  • Jane Kean
    Vision & Eye Research Unit, Anglia Ruskin University, Hartford, ENGLAND, United Kingdom
  • Russell Foster
    Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
  • Susan Downes
    Oxford Eye Hospital, Oxford, United Kingdom
  • Ian Smith
    Respiratory Support and Sleep Centre, Papworth Hospital, Papworth, United Kingdom
  • Footnotes
    Commercial Relationships   Rupert Bourne, None; Dariusz Wozniak, None; Gil Peretz, None; Jane Kean, None; Russell Foster, None; Susan Downes, None; Ian Smith, None
  • Footnotes
    Support  Fight for Sight UK
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5091. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rupert R A Bourne, Dariusz R Wozniak, Gil Peretz, Jane Kean, Russell Foster, Susan Downes, Ian Smith; Is Obstructive Sleep Apnoea Associated with Glaucoma Progression?. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5091.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine whether Obstructive Sleep Apnoea (OSA) is a risk factor for progression in patients with primary open-angle glaucoma (POAG).

Methods : Patients with POAG in the POSAG study (Prevalence of Obstructive Sleep Apnoea in Glaucoma, NCT02713152) underwent nocturnal multi-channel respiratory polygraphy, cardiovascular assessment and medical history review. Retrospective data on progression from the diagnosis of POAG to the study visit were collected. Enrolment required 5+ reliable visual fields (VF; Humphrey Visual Field Analyzer 24-2) and 3+ years of follow up data. Patients were categorised as progressors and non-progressors based on European Glaucoma Society guidelines (EGS) and PROGRESSOR pointwise linear regression (Medisoft, Inc). Rate of VF loss was determined by slope of progression for the whole VF (ProgressorSlope) and decline in mean deviation per year (MD/year). For each patient, the eye with the more severe VF defect (worse MD) was selected, unless only one eye was eligible. OSA was diagnosed based on apnoea-hypopnoea index (AHI) ≥5 (Moderate to severe OSA: AHI≥15). Statistics: independent t test, chi-square, binomial & linear regression.

Results : 159 patients with POAG were included (Mean observation period: 9.5+/-4.3 yrs, mean of 10.6 +/-4.4 VFs per eye. 47.8% of eyes were classified as progressing based on EGS criteria and 51.6% based on PROGRESSOR criteria, with good agreement between the two classifications (κ = 0.61, p=0.00). Within 5 years leading up the diagnostic test for OSA, 37.3% (EGS) and 49% (PROGRESSOR) eyes progressed. Overall, 56.6% of patients were diagnosed with OSA (moderate to severe in 22% of all patients). OSA was not a significant predictor of glaucoma progression irrespective of the classification used or follow up period: odds ratio=1.0 (0.53-1.88), p=0.99 for EGS from baseline, odds ratio=1.39 (0.74-2.6), p=0.31 for PROGRESSOR from baseline. Nor were people with moderate and severe OSA at higher risk of progression in comparison with people without OSA: odds ratio=1.1 (0.72-1.6) for EGS and odds ratio=0.96 (0.64-1.44), p=0.83 for PROGRESSOR. AHI score was not a significant predictor of the rate of progression measured by ProgressorSlope (R2=0.001, p=0.78) or MD/year decline (R2=0.00, p=0.87).

Conclusions : OSA was not a significant contributor to glaucoma progression. Patients with OSA and POAG can be reassured they do not appear to be at any extra risk.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×